- Aeglea BioTherapeutics (NASDAQ:AGLE) initiated with Outperform rating and $37 (368% upside) price target at Evercore ISI. Shares up 5% premarket.
- Alder Biopharmaceuticals (NASDAQ:ALDR) initiated with Neutral rating and $17 (25% upside) price target at Goldman Sachs (NYSE:GS).
- Homology Medicines (NASDAQ:FIXX) initiated with Buy rating and $35 (76% upside) price target at BTIG Research.
- Allscripts Healthcare Solutions (NASDAQ:MDRX) resumed with Overweight rating and $16 (31% upside) price target at JPMorgan (NYSE:JPM). Shares up 6% premarket.
- Athenahealth (NASDAQ:ATHN) resumed with Neutral rating and $159 (11% upside) price target at JPMorgan.
- Allergan (NYSE:AGN) resumed with Buy rating and $200 (25% upside) price target at Citigroup (NYSE:C). Shares up 1% premarket.
- HealthEquity (NASDAQ:HQY) assumed with Overweight rating and $69 (5% upside) at JPMorgan.
- BIO-key International (OTCQB:BKYI) resumed with Buy rating and $5.50 (163% upside) price target at Maxim Group.
- Cardinal Health (NYSE:CAH) upgraded to Outperform at Leerink.
- Prothena (NASDAQ:PRTA) downgraded to Neutral at Oppenheimer and BTIG Research after NEOD001 flop in Alzheimer's.
- Henry Schein (NASDAQ:HSIC) downgraded to Neutral at Goldman Sachs. Shares down 1% premarket.
- ResMed (NYSE:RMD) downgraded to Neutral with a $104 (6% upside) price target at UBS. Shares down 1% premarket.
- Cotiviti Holdings (NYSE:COTV) downgraded to Neutral with a $37 (7% upside) price target at JPMorgan.
- Quality Systems (NASDAQ:QSII) assumed at JPMorgan with Underweight rating and $15 (6% upside) price target at JPMorgan.
- Now read: Cardinal Health: Keen Valuation And Dividend Growth
Original article